Viral Vectors for Immunotherapy: Vaccines and Cancer Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 15378
Special Issue Editor
Interests: viral gene therapy; viral vaccines; gene expression using viral vectors; structural biology; epigenetics; nutrigenomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunology and immunotherapy have seen a major boost during the last few years partly due to the COVID-19 pandemic but also because of progress in cancer immunotherapy. This Special Issue on Viral Vectors of Immunotherapy aims to target both vaccine development and immunotherapy. The goal is to demonstrate the broad range of applications for various viral vectors, such as delivery vehicles for vaccine and tumor antigens, as well as their use in preclinical animal models and in clinical trials. A special emphasis is on self-replicating RNA viruses and their potential use for the delivery of recombinant viral particles, replicon RNA and layered DNA/RNA vectors.
Dr. Kenneth Lundstrom
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- viral vectors
- vaccines
- immunotherapy
- cancer therapy
- self-replicating RNA
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.